Negro R 2004 Quality rating: Poor


Study design: RCT NR Parallel

  • Run-in: None
  • Setting: Single Center
  • Wash out: None
  • Country: Italy

Sample: Number Screened/Eligible/Enrolled Number Withdrawn/Lost to follow-up/Analyzed


Inclusion criteria:

DM2 patients on metformin (up to 3000mg/d); mean SBP <140 and mean DBP <90mm Hg and nocturnal BP falling less than 10% compared to diurnal hours on 24h BP recording at beginning of study.

Exclusion criteria:

Taking antihypertensive medication, diabetic neuropathy and micro- or macroalbuminuria; pancratitis; gastrointestinal and/or malabsorption conditions; heart disease or insufficiency, malignant disease; any liver or renal impairment; history of drug or alcohol abuse; pregnancy or lactation.



  • Mean age: NR years
  • Ethnicity: NR
  • Gender: 0% Female
  • Type 2 diabetes duration (SD): NR

Intervention: added to metformin; non-dippers

Duration: 8 week


Laboratory measures:


P value NR if not specified.

From: Evidence Tables

Cover of Drug Class Review: Thiazolidinediones
Drug Class Review: Thiazolidinediones: Final Report Update 1 [Internet].
Norris SL, Carson S, Thakurta S, et al.
Portland (OR): Oregon Health & Science University; 2008 Aug.
Copyright © 2008, Oregon Health & Science University, Portland, Oregon.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.